Edwards Lifesciences: Strong Business Yet Overvalued Stock
Edwards Lifesciences Has Everything Investors Want Except Value

Image: Seeking Alpha
Edwards Lifesciences Corporation (EW) shows robust growth and a solid market position, but its stock remains overvalued at nearly 47 times earnings. Analysts suggest a 'Hold' rating, anticipating a more favorable entry point around $60 amid competitive and policy challenges.
- 01Edwards Lifesciences boasts a wide economic moat and high growth rates, yet its stock price has been in decline since 2022.
- 02The company reported strong first-quarter results for 2026 and raised its guidance for the year, projecting 9–11% sales growth and improved margins.
- 03Despite positive growth forecasts, the stock trades at approximately 47 times earnings, indicating it may be overvalued at current prices.
- 04Management anticipates double-digit earnings per share (EPS) growth through 2030 along with ongoing share buybacks.
- 05Analysts recommend a 'Hold' rating, suggesting investors wait for a price drop to around $60 for a better buying opportunity.
Advertisement
In-Article Ad
Edwards Lifesciences Corporation (EW) is recognized as a high-quality business with a significant economic moat and impressive growth trajectory. However, its stock has faced a major correction since 2022, currently trading at nearly 47 times earnings and free cash flow, which many analysts consider overvalued. In its recent first-quarter 2026 results, the company reported strong performance and raised its guidance for the year, expecting sales growth between 9% and 11%, along with improving profit margins. Management forecasts double-digit earnings per share (EPS) growth through 2030 and plans to continue share buybacks. Despite these positive indicators, analysts maintain a 'Hold' rating, advising investors to wait for a pullback to approximately $60 before entering, citing valuation concerns and potential competitive and policy risks. This cautious approach reflects the broader sentiment that while Edwards Lifesciences has the fundamentals of a strong business, its current stock price may not offer sufficient value to investors at this time.
Advertisement
In-Article Ad
Advertisement
In-Article Ad
Reader Poll
What do you think about the current valuation of Edwards Lifesciences stock?
Connecting to poll...
Read the original article
Visit the source for the complete story.




